Trials / Completed
CompletedNCT03085940
Role of Hydroxychloroquine to Improve Endothelial Dysfunction in Patients With Rheumatoid Arthritis
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- Indonesia University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Rheumatoid arthritis (RA) increase cardiovascular risk and endothelial dysfunction. Hydroxychloroquine (HCQ) is expected to improve endothelial dysfunction through some metabolic effects. The investigators intend to find the role of HCQ to improve endothelial dysfunction in RA patients. This study will also evaluate correlation HOMA-IR (homeostasis model assessment-estimated insulin resistance), FFA (free fatty acid) and ox-LDL (oxidized-LDL) level change, with endothelial dysfunction improvement.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Hydroxychloroquine | Hydroxychloroquine 400mg once daily initially |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2017-01-20
- Primary completion
- 2017-09-30
- Completion
- 2017-09-30
- First posted
- 2017-03-21
- Last updated
- 2017-10-03
Locations
1 site across 1 country: Indonesia
Source: ClinicalTrials.gov record NCT03085940. Inclusion in this directory is not an endorsement.